Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells

被引:20
|
作者
Maier, Eva [1 ,2 ,3 ]
Attenberger, Felix [1 ,2 ,3 ]
Tiwari, Aadhya [1 ,2 ,3 ]
Lettau, Konstanze [1 ,2 ,3 ]
Rebholz, Simone [1 ,2 ,3 ]
Fehrenbacher, Birgit [4 ]
Schaller, Martin [4 ]
Gani, Cihan [2 ,3 ,5 ]
Toulany, Mahmoud [1 ,2 ,3 ]
机构
[1] Univ Tubingen, Dept Radiat Oncol, Div Radiobiol & Mol Environm Res, D-72076 Tubingen, Germany
[2] German Canc Consortium DKTK, Partner Site Tuebingen, D-69120 Heidelberg, Germany
[3] German Res Ctr DKFZ, D-69120 Heidelberg, Germany
[4] Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany
[5] Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany
关键词
Y-box binding protein 1; colorectal cancer; 5-fluorouracil; RSK; Akt; DNA-REPAIR; IN-VITRO; MONOCLONAL-ANTIBODY; PROGNOSTIC MARKER; KRAS; RESISTANCE; EXPRESSION; MUTATIONS; GROWTH; 5-FLUOROURACIL;
D O I
10.3390/cancers11040562
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
KRAS-mutated colorectal cancers (CRCs) are resistant to cetuximab treatment. The multifunctional Y-box binding protein 1 (YB-1) is overexpressed in CRC and is associated with chemoresistance. In this study, the effects of oncogenic mutated KRAS(G12V) and KRAS(G13D) on YB-1 phosphorylation were investigated in CRC cells. The effects of the inhibition of p90 ribosomal S6 kinase (RSK) on YB-1 phosphorylation, cell proliferation and survival were tested with and without treatment with 5-fluorouracil using pharmacological inhibitors and siRNA. YB-1 phosphorylation status and subcellular distribution in CRC patient tissues were determined by immunofluorescence staining and confocal microscopy. Endogenous expression of mutated KRAS(G13D) and conditional expression of KRAS(G12V) significantly stimulated YB-1 phosphorylation via RSK and were associated with cetuximab resistance. Inhibition of YB-1 by targeting RSK stimulated the Akt signaling pathway, and this stimulation occurred independently of KRAS mutational status. Akt activation interfered with the antiproliferative effect of the RSK inhibitor. Consequently, dual targeting of RSK and Akt efficiently inhibited cell proliferation in KRAS(G13D)-mutated HCT116 and KRAS wild-type SW48 cells. Treatment with 5-fluorouracil (5-FU) significantly enhanced YB-1 phosphorylation in KRAS(G13D)-mutated HCT116 cells but not in KRAS wild-type SW48 cells. Dual targeting of Akt and RSK sensitized HCT116 cells to 5-FU by stimulating 5-FU-induced apoptosis and inhibiting repair of 5-FU-induced DNA damage. YB-1 was highly phosphorylated in CRC patient tumor tissues and was mainly localized in the nucleus. Together, dual targeting of RSK and Akt may be an alternative molecular targeting approach to cetuximab for treating CRC in which YB-1 is highly phosphorylated.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Surmounting Chemoresistance by Targeting the Y-Box Binding Protein-1
    Inoue, Ikuyo
    Matsumoto, Ken
    Yu, Yingnan
    Bay, Boon-Huat
    ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY, 2012, 295 (02): : 215 - 222
  • [2] Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma
    Fujiwara-Okada, Y.
    Matsumoto, Y.
    Fukushi, J.
    Setsu, N.
    Matsuura, S.
    Kamura, S.
    Fujiwara, T.
    Iida, K.
    Hatano, M.
    Nabeshima, A.
    Yamada, H.
    Ono, M.
    Oda, Y.
    Iwamoto, Y.
    BRITISH JOURNAL OF CANCER, 2013, 108 (04) : 836 - 847
  • [3] Targeting the Y-box Binding Protein-1 Axis to Overcome Radiochemotherapy Resistance in Solid Tumors
    Lettau, Konstanze
    Khozooei, Shayan
    Kosnopfel, Corinna
    Zips, Daniel
    Schittek, Birgit
    Toulany, Mahmoud
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (04): : 1072 - 1087
  • [4] MiR-379 inhibits proliferation and induces apoptosis in multiple myeloma by targeting Y-box binding protein 1
    Wang, Yunyun
    Ji, Dexiang
    Chen, Guoan
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (09) : 1843 - 1849
  • [5] Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma
    Y Fujiwara-Okada
    Y Matsumoto
    J Fukushi
    N Setsu
    S Matsuura
    S Kamura
    T Fujiwara
    K Iida
    M Hatano
    A Nabeshima
    H Yamada
    M Ono
    Y Oda
    Y Iwamoto
    British Journal of Cancer, 2013, 108 : 836 - 847
  • [6] The Expression Level and Prognostic Value of Y-Box Binding Protein-1 in Rectal Cancer
    Zhang, Yu
    Zhao, Ping-Wu
    Feng, Gang
    Xie, Gang
    Wang, An-Qun
    Yang, Yong-Hong
    Wang, Dong
    Du, Xiao-Bo
    PLOS ONE, 2015, 10 (03):
  • [7] The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma
    Yasen, M
    Kajino, K
    Kano, S
    Tobita, H
    Yamamoto, J
    Uchiumi, T
    Kon, S
    Maeda, M
    Obulhasim, G
    Arii, S
    Hino, O
    CLINICAL CANCER RESEARCH, 2005, 11 (20) : 7354 - 7361
  • [8] Targeting LINC070974 inhibits lung adenocarcinoma cell proliferation and progression by interacting with Y-box binding protein 1
    Liu, Lin
    Gong, Pengfei
    Li, Xueling
    Zhang, Li
    Niu, Jiale
    Zhu, Jinhui
    Wang, Ziwei
    Long, Xingwang
    Cao, Tenghui
    Liu, Yewen
    Wang, Ganglin
    Fu, Tingming
    Sun, Liang
    Li, Wei
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2025, 57 (02): : 182 - 194
  • [9] Specific knockdown of Y-box binding protein 1 in hepatic progenitor cells inhibits proliferation and alleviates liver fibrosis
    Li, Binghang
    Li, Fei
    Gu, Tianyi
    Guo, Yuecheng
    Shen, Bo
    Xu, Xianjun
    Shen, Zhenyang
    Chen, Liuying
    Zhang, Qidi
    Dong, Hui
    Cai, Xiaobo
    Lu, Lungen
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2022, 921
  • [10] The Communication between the PI3K/AKT/mTOR Pathway and Y-Box Binding Protein-1 in Gynecological Cancer
    Sobocan, Monika
    Bracic, Suzana
    Knez, Jure
    Takac, Iztok
    Haybaeck, Johannes
    CANCERS, 2020, 12 (01)